rHEALTH Nanostrips, Vitals Device, and Fluidics Module to Receive U.S. Patent Protection. Expands patent protection for diagnose yourself, anywhere technology
CAMBRIDGE, Mass., May 21, 2019 — DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, today announced that three separate aspects of its technology platform has received a Notice of Allowance and two Issue Notifications from the U.S. Patent and Trademark Office (USPTO). rHEALTH Nanostrips, and their method of multiplexing as described in “Multi-dye microparticles,” is the subject of a USPTO Notice of Allowance. The SKYE Sensor, described in “Multi-channel vitals device,” is U.S. Patent No. 10,251,565. An important rHEALTH ONE subsystem, the “Fluidics module,” is U.S. Patent No. 10,279,347.
“These recent notifications from the USPTO further solidify our focus on protecting core, breakthrough innovations for taking care of patients wherever they may be,” stated Dr. Eugene Chan, President and CEO.
Nanostrips enable vast multiplexing of medically-relevant tests in a small sample volume. Its concept is to shrink traditional test strips so that tens of thousands of different test strips can be in a drop of blood. The SKYE sensor provides comprehensive, continuous vitals capabilities, including measurements of core body temperature. The fluidics module is part of the rHEALTH ONE, a translational research instrument that provides researchers interested in small volume technology flexibility and ease of use in a laboratory setting.
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.